Menopause - Abstract: Volume 14(6) November December 2007 p 978-984 Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal
The adjacent markers or their steady metabolites in serum or urine were assessed: P-selectin, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, monocyte chemoattractant protein-1, matrix metalloproteinase-9, homocysteine, cyclic guanosine monophosphate, serotonin, prostacyclin, thromboxane, and urodilatin. Matrix metalloproteinase-9 was increased sole by said HT.
The urinary concentrations of cyclic guanosine monophosphate, the ratio of prostacyclin to thromboxane metabolite, and the serotonin metabolite were significantly increased for both HT exercise modes, although the verbal treatment showed a significantly bigger accrual than the transdermal one with account to baseline.
Urodilatin excretion was increased solitary by the vocal regimen. Conclusions: Low-dose transdermal and uttered HTs using E2 and NETA wrest favourable baggage on cardiovascular biochemical markers. If these differences may be attributed to the clashing government routes or to discrepant pharmacokinetic properties remains an emptied question.
Overall low-dose transdermal HT seems to provoke the equivalent avail on the cardiovascular action as spoken HT, as suggested by the results on vascular markers. All rights reserved.
